1. Egrie J, Browne J (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84: Suppl 1 S3–S10
2. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19: 2875–2882
3. Kotasek D, Albertsson M, Mackey J, Berg R, Robinson J, Colowick A Darbepoetin alfa 980291 Study Group USA (2002) Randomized, double-blind, placebo-controlled, dose-finding study of darbepoetin alfa administered once every 3 (Q3W) or 4 (Q4W) weeks in patients with solid tumors. Proc Am Soc Clin Oncol 21: 356a abstract 1421
4. Kotasek D, Berg R, Poulsen E, Colowick A (2000) Randomized, double-blind, placebo controlled, phase I/II dose finding study of ARANESPTM administered once every three weeks in solid tumor patients. Blood 96: 294a–295a, abstract 1268
5. Macdougall IC on behalf of the ARANESPTM UK Study Group (1998) Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anaemia. J Am Soc Nephrol 9: 258a–259a, abstract A1317